Alzheimer's - Dementia, Author Interviews / 06.12.2017
LMTX® Shows Promise As Monotherapy In Mild Alzheimer’s Disease
MedicalResearch.com Interview with:
Professor Claude Wischik
Co-Founder and Executive Chairman
TauRx Pharmaceuticals
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The study TRx-237-005 was the second of two Phase 3 trials conducted by TauRx, and was specifically set up to investigate the efficacy and safety of LMTX® in 800 patients with mild Alzheimer’s disease at a dose of 100 mg twice daily compared to 4 mg twice daily (intended as an inactive control dose) over an 18-month treatment period.
Results from this study were found to be consistent with those from the first Phase 3 study in mild to moderate Alzheimer’s disease, published in The Lancet [(TRx-237-015) Gauthier et al. 2016], indicating that patients obtained no benefit from LMTX® when it was taken in combination with existing approved drugs for Alzheimer’s disease and supporting the hypothesis that LMTX® might be effective as monotherapy at doses as low as 4 mg twice daily. Please refer to the press release for full study results.
(more…)